Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT9B4N3)

• DTT Name: Prostaglandin receptor (PTGR)
• Gene Name: PTGR
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T47077

Molecular Interaction Atlas (MIA) of This DTT

2 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bimatoprost	DMX0E5B	Alopecia	ED70	Approved	[2]
Unoprostone	DMXNR04	Glaucoma/ocular hypertension	9C61	Approved	[1]

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Iclaprim	DM7YNV9	Bacterial infection	1A00-1C4Z	Phase 3	[3]
JB991	DMKU6MW	Skin infection	1F28-1G0Z	Phase 2	[4]

5 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Taprostene	DMA4WY5	Thrombosis	DB61-GB90	Discontinued in Phase 3	[5]
TEI-6122	DM3F5E0	Diabetic complication	5A2Y	Discontinued in Phase 2	[6]
ZD-4953	DM5UCHW	Pain	MG30-MG3Z	Discontinued in Phase 2	[7]
YP-008	DM2N76V	Psoriasis vulgaris	EA90	Terminated	[8]
YP-009	DMPXLG2	Solid tumour/cancer	2A00-2F9Z	Terminated	[9]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IP-1200	DMIX7CP	Erectile dysfunction	HA01.1	Investigative	[10]

References

• [1] Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504.
• [2] Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95.
• [3] Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
• [4] US patent application no. 2006,0041,016, Composition and method for the treatment of psoriasis.
• [5] Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse. J Cardiovasc Pharmacol. 2004 Jun;43(6):795-807.
• [6] The effect of a synthetic 7-thiaprostaglandin E1 derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells.. Br J Pharmacol. 1995 October; 116(4): 2298-2302.
• [7] WO patent application no. 2013,1675,82, Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease.
• [8] CA patent application no. 841416, Method of selecting therapeutic indications.
• [9] YP 009 York Pharma pc preclinical, UK(cancer), R & D Focus Drug News, November 12, 2007
• [10] Clinical pipeline report, company report or official report of Immunologic.